Novartis Boosts Oncology With GSK Assets; Goal Is “Preferential Access”
This article was originally published in The Pink Sheet Daily
Executive Summary
Surprise acquisition of GSK’s marketed oncology products accompanies joint venture on OTC/consumer health; less surprising deals include divesting its animal health business to Lilly and its vaccines business (but not flu vaccines) to GSK.
You may also be interested in...
Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Denmark's IO Vaccine Biotech Attracts Investor Interest
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.
COVID-19 Could Change Attitudes To Flu, Bolster Xofluza
Roche’s first-in-class one-dose antiviral Xofluza has been approved for marketing in the EU to treat influenza in patients aged 12 years or over, and for post-exposure prophylaxis.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: